key: cord-0886956-074vkdta
authors: L, Shashi Bhushan B; Wanve, Sunil; Koradia, Parshottam; Bhomia, Vinay; Soni, Pravin; Chakraborty, Sisir; Khobragade, Akash; Joshi, Shashank; Mendiratta, Sanjeev Kumar; Kansagra, Kevin Kumar; Parihar, Anurag; Sharma, Sunil; Patel, Jatin
title: Efficacy and Safety of Pegylated Interferon-α2b in Moderate COVID-19: A phase 3, randomized, comparator-controlled, open-label study
date: 2021-08-21
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.08.044
sha: 0f63ef631d975ca5cb50e2a7ba5ae828dcd64dd2
doc_id: 886956
cord_uid: 074vkdta

OBJECTIVE: To evaluate the efficacy and safety of pegylated interferon alfa-2b (PEG IFN-α2b) along with the standard of care (SOC) in subjects with moderate Corona Virus Disease-19 (COVID-19). METHODS: In this study, adult subjects with confirmed COVID-19 and moderate signs and symptoms were randomized in a 1:1 ratio to receive either PEG IFN-α2b + SOC or, SOC alone. The primary endpoint was a 2-point improvement in clinical status on day 11, measured by the World Health Organisation 7-point ordinal scale. RESULTS: 250 subjects were randomized to the PEG IFN-α2b + SOC (n = 120) and the SOC (n = 130) arms. The PEG IFN vs SOC arm results for the proportion of subjects with a 2-point improvement were 80.36% vs 68.18%, (P=0.037) on Day 8; 91.60% vs 92.56%, (P= 0.781) on Day 11; and, 94.12% vs 95.93%, (P=0.515) on Day 15. There was a time dependent decrease in the biomarkers in both the arms, no clinically significant changes in lab parameters, and the safety profile was similar. CONCLUSION: PEG IFN-α2b induced early viral clearance, improved the clinical status and decreased the duration of supplemental oxygen. It provides a viable treatment option and can limit the spread of virus.

A novel coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in December 2019 in patients in Wuhan city of China, and has since been designated as a pandemic worldwide (Cucinotta and Vanelli, 2020, Spinelli and Pellino, 2020) . As of 06 May 2021, more than 154 million confirmed cases and 3.2 million deaths have been reported worldwide. In India, there have been 21, 077, 410 confirmed cases including 230, 168 deaths reported till 06 May 2021 (WHO, 2021) . The clinical spectrum of SARS-CoV-2 infection appears to be wide, encompassing asymptomatic infections, mild upper respiratory tract illness, fatigue, fever, myalgias, severe life-threatening viral pneumonia which requires admission to hospital and death (Cortinovis et al., 2021) .

The presence of comorbidities, particularly hypertension, diabetes, obesity, and smoking are factors which increase the risk of severe disease (Zheng et al., 2020 , Chen et al., 2020a . The characteristics of Corona Virus Disease-19 (COVID-19) may differ depending on the demographic and epidemiological profiles of each country.

Till date, only dexamethasone and remdesivir have shown efficacy in randomized trials of hospitalized patients with COVID-19 and an interim analysis of a monoclonal antibody infusions have been shown to have a faster viral clearance in outpatients. (Beigel et al., 2020 , Horby et al., 2020 , Chen et al., 2020b . As seen in other acute viral infections, timely initiation of antiviral therapy for COVID-19 might improve clinical outcomes (Aoki et al., 2003) however, very few studies among outpatients have been completed.

Type I interferons (IFN) are broad-spectrum antivirals that are body's natural first line of defense and secreted subsequent to viral replication inside the cell (tenOever et al., 2016) .

They carry out their action by binding to and activating the type 1 IFN receptors and activating the Janus kinase/signal transducer activator of transcription (JAK/STAT) pathway.

Activation of the JAK/STAT pathway increases the expression of IFN-stimulated genes (ISGs) in multiple tissues involved in the antiviral response including both, direct inhibitory effects on viral replication and supporting an immune response to clear viral infection (Lazear et al., 2019) . Recent developments suggest an important association between type I IFNs and SARS-CoV-2 infection and disease (Blanco-Melo et al., 2020; Hadjadj et al., 2020; Bastard et al., 2020; Zhang et al., 2020) . Levels of IFN alpha dropped in direct correlation with disease severity (Hadjadj et al., 2020) . Sera of Covid-19 patients did not show any detectable levels of IFN beta (Blanco-Melo et al., 2020) . Around 13.7% of severe disease patients were found to be carrying neutralizing antibodies against IFN alpha and other type I IFNs and had low or undetectable serum IFN-α2b levels during acute disease . Another 3.5% patients had inborn errors of type I IFN immunity .

In vitro, a direct antiviral effect of interferon alfa against SARS-CoV-2 has been clearly demonstrated (Lokugamage et al., 2020; Mantlo et al., 2020) . In our own studies an IC50 of 15.6 fM was established for PEG IFN-α2b in a setup where Vero E6 cells were pretreated with the drug before being challenged with SARS-CoV-2. In an exploratory study with 77 COVID-19 hospitalized patients, given IFN-α2b either alone or with arbidol (a broadspectrum antiviral compound) it was observed that those who received IFN-α2b demonstrated a significant reduction in the duration of detectable virus in the upper respiratory tract and reduced blood levels of inflammatory markers, Interleukin-6 (IL-6) and C-reactive Protein (CRP) (Zhou et al, 2020) . Similarly in a retrospective analysis of 446 hospitalized COVID-19 patients it was observed that those who were given IFN-α2b demonstrated reduced inhospital mortality not associated with hospital discharge (Wang et al, 2020) . Synthetic glucocorticoid dexamethasone has been proven to reduce COVID-19 mortality by suppression of an overactive immune response; however this takes place at the cost of suppression of IFN-α2b a crucial component of anti-viral response. Among patients receiving glucocorticoids, early interferon therapy was associated with earlier hospital discharge (adjusted HR 1.68, 95% CI 1.19-2.37) and symptom relief (adjusted HR 1.48, 95% CI 1.06-2.08), lower prevalence of prolonged viral shedding (adjusted OR 0.24, 95% CI 0.10-0.57) (Lu et al, 2021) . A crucial role of type I IFNs such as IFN-α2b in the protective immunity against SARS-CoV-2 is clearly getting established.

PEG IFN-α2b is a covalent conjugate of a recombinant type I interferon, IFN-α2b with monomethoxy polyethylene glycol. Both IFN-α and PEG IFN-α2b type of drugs have been used clinically to treat Hepatitis B and C viruses for several years. A phase 2 randomized study of 40 moderate COVID-19 patients demonstrated that a single dose of PEG IFN-α2b

given along with Standard of care (SOC) was able to bring about an early negative reverse transcription polymerase chain reaction (RT-PCR) along with improvement in clinical symptoms by Day 15 in comparison with those who were given SOC alone (Pandit et al., 2021) . However, quantitative RT-PCR was not performed and a small sample size were the limitations in this phase 2 study. We now present the findings from our phase 3 study involving 250 moderate COVID-19 patients.

This was a phase 3, multi-centric, randomized, comparator-controlled, open-label study to evaluate the efficacy and safety of a single dose of PEG IFN-α2b in the treatment of adult patients diagnosed with SARS-CoV-2, and the study was undertaken at 20 study centers across India. Eligible subjects were randomly assigned in a 1:1 ratio to receive either PEG IFN-α2b along with SOC or SOC alone.

This study was initiated after obtaining the approvals of the Ethics Committee (EC), Drugs Controller General of India (DCGI) (dated 14 December 2020) and the safety, efficacy and study conduct was overseen by an Independent Data Safety Monitoring Board. This study was conducted in accordance with the applicable local regulations and registered with the CTRI (CTRI/2020/12/029855).

Individuals with suspected COVID-19 were recruited from 20 study centers across India from 16 December 2020 to 25 March 2021. Key inclusion criteria were age ≥18 years, RT-PCR confirmed SARS-CoV-2 infection, pneumonia with no signs of severe disease, respiratory rate (RR) ≥24 breaths/minute, SpO2 90% to 94%, and for female patients of child-bearing potential, a negative pregnancy test was required prior to treatment. Key eligibility criteria is provided in Supplementary Material.

Eligible subjects were randomized in a 1:1 ratio to either PEG IFN-α2b (1 µg/kg subcutaneous [SC] injection, single dose) plus SOC or SOC alone. Standard of care treatments (i.e., antipyretics, cough suppressants, antibiotics, steroids, vitamins, anticoagulants, hydroxychloroquine and antivirals e.g. remdesivir) were administered as per the COVID-19 clinical management guidelines of the ministry of health, Government of India and the individual institutional practice. Randomization was generated using SAS ® software (Version 9.4). Each vial of PEG IFN-α2b was reconstituted with 0.7 ml of water for injection for administration of up to 0.5 ml of solution. Each 0.5 ml of solution for SC injection delivers 100 μg of PEG IFN-α2b. All subjects were hospitalized, RT-PCR tests in pharyngeal swab performed at screening, Day 7, Day 11, Day 15 and Day 29.

The primary outcome was to evaluate the clinical efficacy of PEG IFN-α2b based on change in ordinal scale at day 11 (two-point improvement in the WHO 7-point ordinal scale) (WHO solidarity trial consortium, 2021) consisting of the following categories: 1, not hospitalized, no limitations of activities; 2, not hospitalized, limitation on activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, on non-invasive ventilation or high flow oxygen devices; 6, hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) ; and 7, death.

The secondary efficacy endpoints were to evaluate the clinical efficacy of PEG IFN-α2b based on change in ordinal scale at day 8, 11, and 15, the proportion of subjects with adverse events (AEs) that occurred on or after the first dose of PEG IFN-α2b, qualitative PCR for SARS-CoV-2 in pharyngeal swab, occurrence and duration of supplemental oxygen and mechanical ventilation, time to resolution of clinical signs and symptoms, duration of hospitalisation, change from baseline in white blood cell count, haemoglobin, platelets, creatinine, glucose, total bilirubin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) till Day 29 and change from baseline in CRP, D-dimer, ferritin, and IL 6 till Day 29.

Safety assessments were based on physical examinations, vitals, laboratory tests and the incidence and severity of AEs.

The primary efficacy endpoint was the proportion of subjects having improvement in condition (clinical status) measured using the WHO 7-point ordinal scale for clinical improvement during the dosing period, and was presented descriptively as frequency and percent.. Treatment effect was assessed using Fisher's exact test for active treatment (PEG IFN-α2b plus SOC) versus SOC. Non-parametric test, Wilcoxon rank sum test was used to assess the change in score from baseline within the group.

Secondary endpoints, qualitative RT-PCR, requirement/duration of supplemental oxygen, mechanical ventilation and time to resolution of signs and symptoms were analyzed same as the primary endpoint by non-parametric Wilcoxon Rank Sum Test. Comparison of the following biomarkers (CRP, IL-6, D-dimer and ferritin) between treatment groups were analyzed using an analysis of covariance (ANCOVA) model treatment as fixed effect and baseline value as covariate.

Statistical significance was tested at a two-sided p-value of 0.05. Results are presented as mean ± SD (in the text and tables).

Post-hoc analysis was performed for the proportion of patients with a two point improvement in the WHO 7-point ordinal scale at day 8 and the data was analyzed in the sub groups of patients 'with and without Remdesivir' and 'with and without steroids'.

The populations and sample size calculation are provided in Supplementary Material.

A total of 273 subjects were screened and 23 subjects were screen failures or not enrolled into the study and 250 subjects were administered the study medication as per randomization: 120 subjects were administered the test and 130 the reference product.

Of the 250 subjects, 14 subjects were discontinued from the study: 7 subjects in each of the treatment arms. The reason for discontinuation from the study was serious adverse event (2 subjects), lost to follow up (6 subjects), and consent withdrawn (6 subjects).

Of the 250 subjects randomized, 242 (96.80%) subjects comprised the modified intent-totreat (mITT) and 250 (100.00%) subjects comprised safety populations, respectively. One subject was not administered the reference medication.

Of the 250 subjects, 177 (70.80%) were male and 73 (29.20%) were female. The mean age was 49.60 ± 14.98 years in PEG IFN-α2b plus SOC group and 50.14 ± 15.61 years in SOC group alone. Overall, demographic characteristics of the study subjects were comparable across the treatment groups (Table 1 ). The subject disposition is provided in Figure 1 .

The primary outcome was to evaluate the clinical efficacy of PEG IFN-α2b based on change in ordinal scale (two-point improvement in the WHO 7-point ordinal scale) at day 11. Subjects in the PEG IFN-α2b plus SOC group achieved more reduction in the mean score (measured by 7-point ordinal) from baseline to Day 15 than the subjects in the SOC group.

The mean (SD) change in score from baseline to Day 15 was -2.34 (0.90) and -2.24 (0.69) in PEG IFN-α2b plus SOC group and SOC group, respectively.

Out of the 119 subjects in the PEG IFN-α2b plus SOC group, 103 (91.15%), 114 (97.44%) and 116 (98.31%) were observed as negative RT-PCR at Day 7, Day 11 and Day 14, respectively ( In mITT population, out of the 242 subjects, total 131 subjects required oxygen support: 64 (61.54%) subjects in PEG IFN-α2b + SOC group and 67 (59.29%) subjects in SOC group alone. Subjects in the PEG IFN-α2b + SOC group had a shorter duration of supplemental oxygen than subjects in the SOC group alone (Figure 2) , median, 56.00 hours, as compared with 84.00 hours; p<0.05. PP population presented in Supplementary Table 3. Of the 242 subjects, 2 (1.69%) subjects in PEG IFN-α2b + SOC group and 1 (0.81%) subjects in SOC group alone required mechanical ventilation. There was no statistical significant difference observed in mechanical ventilation in PEG IFN-α2b + SOC group compared to SOC alone during the study. PP population presented in Supplementary Table 4 .

Subjects in the PEG IFN-α2b + SOC group had a shorter duration of resolution of signs and symptoms than subjects in the SOC group alone (median, 5 days, as compared with 6 days; p<0.05). PP population presented in Supplementary Table 5 .

Subjects observed a similar duration of hospitalization in both the treatment groups during the study in mITT population (median, 9 days; P˃0.05). Similar results obtained in PP population (See, Supplementary Table 6 ).

Serial laboratory measurements of blood levels for CRP, IL-6, D-dimer and ferritin were also conducted. There was a decrease in both the groups but no significant differences between the treatment groups for any of these parameters during the study.

In the analysis of the proportion of patients with a two point improvement in the WHO 7 point ordinal scale at day 8 in the sub groups of patients 'with and without Remdesivir', the following results were observed. For the 'With Remdesivir' analysis, in the PEG IFN-α2b + SOC + Remdesivir group (n=25), the improvement was seen in 15 patients (60.00%), whereas in the SOC + Remdesivir group (n=27), the improvement was seen in 18 patients (66.67%) and the P value was 0.617. For the 'Without Remdesivir' analysis, in the PEG IFN-α2b + SOC (n=87), the improvement was seen in 75 patients (86.21%), whereas in the SOC group (n=83), the improvement was seen in 57 patients (68.67%) and the P value was 0.0061 (Supplementary Tables 7 and 8 ).

In the analysis of the proportion of patients with a two point improvement in the WHO 7 point ordinal scale at day 8 in the sub groups of patients 'with and without steroids', the following results were observed. For the 'With steroids' analysis, in the PEG IFN-α2b + SOC + steroids group (n=71), the improvement was seen in 61 patients (85.92%), whereas in the SOC + steroids group (n=74), the improvement was seen in 50 patients (67.57%) and the P value was 0.0091. For the 'Without steroids' analysis, in the PEG IFN-α2b + SOC (n=41), the improvement was seen in 29 patients (70.73%), whereas in the SOC group (n=36), the improvement was seen in 25 patients (69.44%) and the P value was 0.902 (Supplementary Tables 9 and 10).

Of the 250 subjects, 21 (8.47%) subjects had at least one treatment emergent adverse event (TEAE) during the treatment period: 8 (6.67%) subjects in PEG IFN-α2b + SOC group and 13 (10.00%) subjects in SOC group alone (See Table 3 ). None of the subjects were discontinued from the study due to AEs in any of the treatment group. All AEs were followed up until the subject was 'recovered' or 'recovered with sequelae' or until the end of post treatment follow-up, whichever came first. There were two deaths reported in test arm during the study. One subject had sudden cardio pulmonary arrest. The event was not related to study drug as declared by the investigator. Second subject had COVID-19, which was not related to the study drug declared by the sponsor and investigator.

The reported preferred term (PT) of TEAEs in PEG IFN-α2b + SOC treatment group were: chest pain 1 (0.77%), asthenia 1 (0.77%), myalgia 1 (0.77%), headache 3 (2.31%), respiratory distress 1 (0.77%) and pruritus 1 (0.77%). While in SOC treatment group alone were: chest pain 1 (0.83%), constipation 2 (1.67%), diarrhea 1 (0.83%), gastritis 1 (0.83%), nausea 1 (0.83%), asthenia 1 (0.83%), back pain 1 (0.83%), cough 1 (0.83%), respiratory distress 2 (1.67%) and pruritus 1 (0.83%).

Two cases of deaths were reported in the test arm and they were due to the progression of the underlying COVID-19 infection. The causality assessment performed by the study investigators and also evaluated by the Ethics committees and the DSMB, termed them as "Not related" to the study drug in both the cases.

No apparent difference was observed in any of the biomarker and laboratory parameters between the treatment groups. No clinically relevant findings from clinical examination, vital signs and electrocardiogram (ECG) evaluations were attributed to PEG IFN-α2b. Overall, single dose of PEG IFN-α2b was safe and well tolerated in the study.

IFN-α2b is a member of type I interferons that are known to be poorly expressed after infection with SARS-CoV-2 virus. Treatment with IFN-α2b through the intranasal and the subcutaneous delivery routes has been studied in the treatment of COVID-19 and demonstrated to help in the alleviation of disease. On the basis of these observations we tested a long acting form of IFN-α2b, PEG IFN-α2b, in the treatment of moderate COVID-19 patients.

In our study, moderate COVID-19 disease patients who were given a single dose of PEG IFN along with SOC showed a significant (P = 0.0379) 2-point improvement on the 7-point WHO ordinal scale on day 8 when compared to those who received SOC only. This difference between the two treatment arms was not significant on days 11 and 14. The significant difference on day 8 in the ordinal scale correlated very well with the significant difference (P = 0.01) in the qualitative RT-PCR data for the two groups on the previous day (day 7).

Type I interferons such as IFN alpha-2b are produced as a first response to most viral infections by the affected cells. In contrast to other respiratory viruses, a COVID-19 viral infection does not seem to produce a strong early type I interferon response (Blanco-Melo et al., 2020) and therefore, intervention with PEG IFN may have filled this gap in the early response to COVID infection, leading to a reduction in viral load, followed by a clinical improvement on the WHO ordinal scale as well as the time to resolution of clinical signs and symptoms. In this study, patients given PEG IFN showed a significantly reduced requirement for supplemental oxygen as well as early resolution of signs and symptoms in comparison with those who were not. PEG IFN mediated early reduction of viral load may have helped the lungs in performing their function better likely due to a reduced level of lung infection, although this was not directly studied in this clinical trial. Nevertheless the phenomenon appeared real, as a similar observation was also made in our Phase 2 clinical trial involving a much smaller group of moderate COVID-19 patients (Pandit et al., 2021) .

The lack of a difference between the two groups in terms of duration of hospitalization may have been influenced by the discharge decisions of the various hospitals during the pandemic, being dependent upon a variety of other reasons than the overall health status of the patient.

Biomarkers are important parameters to evaluate safety of the product and predict the severity/progression of the disease. In this study there was no apparent difference observed in any of the biomarkers (CRP, IL-6, D-dimer and ferritin) and laboratory parameters between the treatment groups. During the study the safety evaluations has been done with different parameters such as clinical examination, vital signs, electrocardiogram (ECG) and monitor the AEs. There was no statistically significance difference between both the treatment arms.

As per the results of WHO solidarity trial, drugs such as hydroxychloroquine, remdesivir, lopinavir and interferon beta did not show improvement in hospitalized patients with COVID-19, when measured by mortality, initiation of ventilation, and duration of hospital stay ( WHO solidarity trial consortium, 2021).

Given that patients in our study were of moderate disease status most of them eventually became virus free. The statistically significant difference for RT-PCR negativity observed at the early time point (day 7) clearly demonstrates that Peg IFN alfa-2b treatment benefitted the patients. A lack of statistically significant difference at a later time point (day 11) suggests that the majority of moderate patient population eventually becomes virus free. Therefore the benefit of Peg IFN alfa-2b therapy is in the early cure of moderate patients and thereby minimising the risk of their getting severe disease.

Upon sub-group analysis it was observed that all differences between the test and the reference arms were even more significantly improved in the subgroups that received steroids. Steroids by far have been the most important class of drugs in the therapy of COVID-19 disease. Steroids being immunosuppressant in nature, are known to suppress the expression of type I interferons as well (Singanayagam et al., 2018) . Combining Peg IFN with steroids likely eliminated this defect by supplementing this important cytokine, leading to a highly significant improvement in RT-PCR negativity, change on WHO ordinal scale, duration of supplemental oxygenation, as well as, time to resolution of clinical signs and symptoms in comparison to those patients who received steroids but not Peg IFN. These observations echo the recent observations from the retrospective analysis of hospitalized patients where those given early interferon alpha therapy along with glucocorticoids showed a significant improvement in days of hospitalization, clinical symptoms and virus shedding (Lu Y. et al., 2021) .

COVID-19 is a complex disease involving an interplay of multiple host factors; inflammatory chemokines, cytokines, complement, and various other factors have been implicated in the disease pathology, initially triggered by the event of viral infection, and subsequent damage of infected cells (Perico et al., 2021) . Therefore, apart from the potentially insufficient early type I interferon production in patients, an interplay of one or more of the above factors may have been playing a more dominant role in the disease pathology in some other patients.

Beyond the observation of statistically significant differences on day 8, these other factors may have been responsible for the lack of difference in clinical status on days 11 and 15, despite the fact that almost all (96.58% to 98.35%) the subjects in the study were RT-PCR negative by then.

Early treatment with PEG IFN-α2b induced early viral clearance and improved the clinical status of patients with moderate COVID-19 disease. It also decreased the duration of supplemental oxygen. Treatment with PEG IFN-α2b provides a viable treatment option during the current pandemic situation. It can also limit the spread of virus in the community.

In this study, interactive voice response system (IVRS) or interactive web response system (IWRS) was not used for randomization, and expectedly, has led to an imbalance in the numbers randomized because of competitive recruitment at the study sites. Also, baseline stratification was not performed for co-morbid conditions. With respect to the quantitative RT-PCR data, there was no uniformity in reporting the CT values between the different pathology laboratories and a few labs reported only the qualitative data. Hence, we could not perform a meaningful analysis for the quantitative RT-PCR data. Regarding the oxygen requirement, as per the protocol, moderate subjects were enrolled in the study and as per the standard COVID-19 treatment guidelines were supposed to be given oxygen. But individual sites followed their own institutional practice and have given oxygen based upon the clinical judgment of the investigators as well as the SpO2 level changes (some of the subjects were at oxygen support at the time of enrollment). The subgroup analysis performed in this study are the post hoc analysis and was not defined in the study protocol. Standard of care was not uniform for all the centres considering the investigator discretion and different signs and symptoms of patients although centre-wise SOC was uniform for test and reference subjects.

Subjects were on multiple treatments (SOC) and hence some of the AEs may have been masked by the treatments.

This trial was sponsored and funded by Cadila Healthcare Ltd., Ahmedabad, India. Authors 

Written informed consent was obtained from all participants at the time of screening. This trial was initiated after obtaining the approvals of ECs, DCGI and registering the trial with the CTRI. This trial was conducted in accordance with the applicable local regulations.

All the authors were involved in the conceptualization of the study, data interpretation, manuscript writing, and manuscript review. Shashank Joshi, Kevinkumar Kansagra and Jatin Patel were involved in the conceptualization of the study, data interpretation and manuscript writing. Manjunath Krishnappa and Richa Vellanki were part of the study conduction and Manjunath was also involved in data interpretation. Sunil Sharma and Jay Bhavsar were 

N=number of subjects in treatment; n=number of subjects with available data for treatment Chi-Square test has been used to calculate p-value 95% CI was calculated using risk difference Risk difference is defined as the difference [(Pegylated IFN-α2b + SOC) -SOC)] pvalue < 0.05 was considered as statistically significant SOC=Standard of Care N=number of subjects in treatment n=number of subjects in treatment by available data for improvement p-value has been calculated using Fisher's Exact test for day 7 and Chisquare for all other day-11 and day-15 p-value < 0.05 was considered as statistically significant If a subject has multiple occurrences of an AE, the subject is presented only once for the correspondin g AE. 

Early administration of oral oseltamivir increases the benefits of influenza treatment

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Remdesivir for the treatment of COVID-19-final report

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

clinical course of severe and critically ill patients with coronavirus disease 2019 (COVID-19): a comparative study

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19

Long-term follow-up of recovered patients with COVID-19. The Lancet

WHO declares COVID-19 a pandemic

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Dexamethasone in hospitalized patients with COVID-19 preliminary report

Shared and Distinct Functions of Type I and Type III Interferons

Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV

Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19

Antiviral activities of type I interferons to SARS-CoV-2 infection

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations

COVID-19 pandemic: perspectives on an unfolding crisis

World Health Organization. Solidarity" clinical trial for COVID-19 treatments

The evolution of antiviral defense systems

Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell host & microbe

World Health Organization. WHO coronavirus disease (COVID-19) dashboard

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis

Interferon-α2b Treatment for COVID-19